ALKERMES | ALKS - Selling And Administration Expenses


ALKERMES reported $190.54M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.12B 305M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
J&J USD 6.25B 168M Sep/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 2.86B 25M Sep/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Otsuka Holdings JPY 281.85B 7.41B Sep/2026
Ovoca Bio EUR 617K 15K Dec/2025
Pfizer USD 3.28B 132M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026